Bring your commercial challenges to us.
Healogix combines deep therapeutic expertise with rigorous methodology to help healthcare executives make clearer, faster strategic decisions.
The questions that keep you up at night should not get a surface-level answer
Most research firms deliver data dumps. We deliver decisions. Here is how we shift from information to insight.
Deep therapeutic literacy
We do not just read the protocol. Our team has lived through the science across multiple categories. That means fewer fact-checking delays and faster strategic signal.
Methodology built for biopharma
Generic survey design wastes panel time. We use adaptive choice-based conjoint, Bayesian modeling, and qualitative techniques tuned for rare disease, oncology, and specialty care.
Global reach without the overhead
Our network spans North America, Europe, and Asia-Pacific. We engage KOLs, physicians, and payers in their local market without a five-office cost structure.
Real-world evidence integration
Claims data, medical records, and patient-reported outcomes do not belong in separate silos. We integrate them into a single commercial narrative for launch and life-cycle planning.
Messenger credibility assessment
Who says the message matters as much as the content. We evaluate not just what resonates but which stakeholder type carries the most weight with your audience.
Hours of analysis, condensed into one chart
Each data set we build runs through rigorous checks. The result is a commercial signal you can actually act on.
200+
Indicators modeled
85%
Forecast accuracy
40+
Therapeutic areas
30+
Countries covered
Questions about our approach?
Our expertise is built on evidence, not hype. Here is what that looks like in practice.
How does healogix differ from other market research firms?
We combine deep therapeutic expertise with rigorous methodology and global reach. Our team has worked across enough categories and markets to know when standard approaches fall short — and we adapt accordingly.
Do you only work with large pharmaceutical companies?
No. We work with executives at companies of various sizes who face real development and marketing decisions. Our scale and scope let us handle complex global issues, but our approach is practical for the specific challenge at hand.
What does a typical engagement look like?
It starts with a focused conversation about the decision you are facing. We define the question, scope the methodology, and execute with the same rigor whether it is an early-stage assessment or a life-cycle management project.
How quickly can healogix deliver insights?
Timing depends on the complexity of the question and the markets involved. We structure our work to match the pace of your decision-making — moving fast when speed matters, thorough when depth is required.
What therapeutic categories do you cover?
Our team has experience across a broad range of therapeutic areas. We bring deep commercial and methodological expertise to each engagement, so you get analysis grounded in category-specific knowledge, not generic templates.
How do you ensure the research is actionable?
Every study is designed from the decision backwards. We focus on what will clarify your commercial options, not what fills a report. The output is built to support the conversation in the boardroom, not gather dust on a shelf.
Still have questions?
Every commercial challenge is different. Let's talk about yours.
Evidence that guides real decisions
We needed a clear go-to-market forecast for a rare disease asset entering a crowded landscape. The team delivered a pricing and access model that shaped our Phase III endpoint decisions.
Ravi Kapoor
Vice President, Global Commercial Strategy
The message optimization study didn't just rank our claims — it showed us which ones would actually move prescribing behavior. We restructured our entire launch campaign around the findings.
Michelle Torres
Director, Brand Marketing, Top-10 Pharma
We brought healogix in for a late-cycle brand rejuvenation. The segmentation analysis uncovered two physician segments we were completely ignoring. Our next campaign was built around that insight.
David Chen
Executive Director, Market Access
One team. Every commercial question answered.
From early-stage opportunity assessment to life-cycle management, we bring depth across every phase of a product's journey.